GLPG
HealthcareGalapagos N.V. · Biotechnology · $2B
What is Galapagos N.V.?
Galapagos N.V. is a Belgian biopharmaceutical company focused on discovering and developing medicines for diseases with high unmet medical need. Its pipeline spans inflammation, fibrosis, and rare diseases, supported by major collaboration agreements.
Galapagos generates revenue primarily through collaboration agreements with partners including Gilead Sciences, AbbVie, and Novartis, while advancing its own clinical pipeline. The company focuses on identifying novel drug targets and progressing candidates through clinical trials across multiple therapeutic areas, including rheumatology, pulmonology, and rare diseases.
Galapagos was incorporated in 1999 and is headquartered in Mechelen, Belgium.
- Filgotinib — a JAK1 inhibitor in trials for rheumatoid arthritis, Crohn's disease, and related inflammatory conditions
- Toledo molecule program — targeting inflammation via GLPG3970, GLPG4399, and GLPG4876
- IPF pipeline — GLPG4716 and Ziritaxestat for idiopathic pulmonary fibrosis
- Rare disease research — GLPG2737 in Phase 2 for autosomal dominant polycystic kidney disease
Is GLPG a Good Stock to Buy?
UQS Score rates GLPG as Good overall, reflecting a balanced profile with notable strengths and areas to watch.
The Risk pillar stands out as a clear strength, suggesting the company carries a relatively conservative financial profile compared to many clinical-stage peers. The Valuation pillar is rated Attractive, meaning the market may not be fully pricing in the company's pipeline potential. Growth is also rated Good, pointing to meaningful forward opportunity.
The Moat pillar is rated Weak, reflecting the competitive and uncertain nature of drug development, where pipeline setbacks can quickly erode advantages. Quality is Neutral, indicating room for improvement in underlying business fundamentals.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does GLPG pay dividends?
No — Galapagos N.V. does not currently pay a dividend.
Galapagos does not currently pay a dividend, which is typical for clinical-stage biopharmaceutical companies. Capital is directed toward research, clinical trials, and pipeline advancement rather than shareholder distributions. Investors in GLPG are generally seeking long-term value creation through drug development rather than income.
When does GLPG report earnings?
Galapagos reports earnings on a quarterly cadence, consistent with standard practice for companies listed on US exchanges.
Results tend to be shaped by collaboration milestone payments, research and development spending, and clinical trial progress rather than traditional product revenue. Pipeline updates and partnership developments often carry as much weight as headline financial figures for investors tracking GLPG.
For the most recent quarter's results and guidance, visit Galapagos N.V.'s official investor relations page.
GLPG Price History
-62.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Galapagos N.V.?
Based on Galapagos N.V.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
GLPG Long-term Outlook
The Good Growth rating suggests Galapagos has meaningful forward potential, largely tied to clinical milestones across its inflammation and fibrosis programs. The Strong Risk rating indicates the company is positioned with a degree of financial resilience uncommon among peers of similar size. However, the Weak Moat rating is a reminder that pipeline-dependent companies face binary outcomes — successful trial readouts can accelerate value creation, while setbacks can rapidly shift the outlook.
Growth drivers
- Advancement of filgotinib across multiple inflammatory indications
- Milestone and royalty payments from Gilead, AbbVie, and Novartis collaborations
- Pipeline progression in idiopathic pulmonary fibrosis and rare kidney disease
Key risks
- Clinical trial failures or regulatory setbacks across key pipeline assets
- Dependence on collaboration partners for a significant portion of revenue
- Competitive pressure from established players in JAK inhibitor and fibrosis markets
GLPG vs Peers
Galapagos operates in a competitive clinical-stage landscape alongside several focused biopharmaceutical companies.
AnaptysBio focuses on antibody-based therapies for inflammatory diseases, taking a different biological approach than Galapagos's small-molecule JAK inhibitor strategy.
Tyra Biosciences targets FGFR-driven diseases with a precision medicine focus, concentrating on a narrower set of genetic targets compared to Galapagos's broader pipeline.
Sionna is focused on cystic fibrosis, overlapping with one area of Galapagos's research, but with a more concentrated single-disease pipeline.
Frequently Asked Questions
What does Galapagos N.V. do?
Galapagos is an integrated biopharmaceutical company that discovers, develops, and aims to commercialize medicines for diseases with high unmet need. Its pipeline covers inflammatory conditions, idiopathic pulmonary fibrosis, and rare diseases. The company also earns revenue through collaboration agreements with major pharmaceutical partners including Gilead Sciences, AbbVie, and Novartis.
Does GLPG pay dividends?
Galapagos does not currently pay a dividend. As a clinical-stage biopharmaceutical company, it reinvests available capital into research and development rather than returning cash to shareholders. Investors focused on income may want to consider this before investing.
When does GLPG report earnings?
Galapagos reports on a quarterly cadence, as is standard for US-listed equities. For exact dates and the most recent financial results, check the investor relations section of the Galapagos N.V. official website.
Is GLPG a good stock to buy?
UQS Score rates GLPG as Good overall. The Risk pillar is Strong and Valuation is Attractive, which are positive signals. However, the Moat pillar is Weak, reflecting the inherent uncertainty of drug development. Whether GLPG fits your portfolio depends on your risk tolerance and investment goals — view the full breakdown on UQS Score.
Is GLPG overvalued?
The UQS Valuation pillar for GLPG is rated Attractive, suggesting the stock may be trading at a reasonable level relative to its fundamentals and pipeline potential. This does not guarantee future price appreciation, but it indicates the market may not be fully pricing in the company's assets. Pro members can access the detailed valuation metrics.
How does GLPG compare to its competitors?
Galapagos distinguishes itself through a broad multi-indication pipeline and established collaboration agreements with large pharmaceutical companies. Peers like AnaptysBio, Tyra Biosciences, and Sionna Therapeutics tend to have narrower therapeutic focuses. UQS Score provides side-by-side pillar comparisons for Pro members.
What is GLPG's market cap bracket?
Galapagos N.V. is currently classified as a small-cap company. This places it in a category where pipeline developments and partnership milestones can have an outsized impact on market valuation compared to larger, more diversified pharmaceutical companies.
Who founded Galapagos N.V.?
Galapagos N.V. was incorporated in 1999. Founding details are widely available through the company's official history and public filings. The company has since grown into a recognized European biopharmaceutical player with a global clinical development footprint.
Is GLPG a long-term quality investment?
From a long-term quality perspective, GLPG's Strong Risk rating and Attractive Valuation are encouraging signals. However, the Weak Moat rating highlights that the company's competitive position depends heavily on clinical outcomes and partnership continuity. Long-term quality indicators are best assessed through the full UQS pillar breakdown available to Pro members.
What is the main competitive advantage of Galapagos?
Galapagos's primary advantages include its established collaboration network with Gilead, AbbVie, and Novartis, which provides both funding and validation for its pipeline. Its JAK1 inhibitor platform and multi-indication development strategy give it breadth across inflammatory diseases. That said, the UQS Moat pillar rates this advantage as Weak relative to the broader sector.
Unlock Full GLPG Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access detailed financial metrics and trend data
- ✓Compare GLPG side-by-side with competitors on every pillar
- ✓See how GLPG ranks within the Healthcare sector
- ✓Get the complete analyst-style view available to Pro members
Pro Analysis
GLPG — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 67.2 | 65.7 | 33.0 | 62.5 | 100.0 | 100.0 | -0.9 |
| May 12, 2026 | 68.1 | 69.3 | 33.0 | 62.5 | 100.0 | 100.0 | +2.8 |
| Apr 4, 2026 | 65.3 | 58.2 | 33.0 | 62.5 | 100.0 | 100.0 | -1.1 |
| Apr 2, 2026 | 66.4 | 62.8 | 33.0 | 62.5 | 100.0 | 100.0 | — |
GLPG — Pillar Breakdown
Quality
— 65.7/100 (25%)Galapagos N.V. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 62.5/100 (20%)Galapagos N.V. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 100.0/100 (15%)Galapagos N.V. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 100.0/100 (15%)Galapagos N.V. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
Enterprise value multiple relative to sector median.
Moat
— 33/100 (25%)Galapagos N.V. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for GLPG.
Score Composition
Financial Data
More Stock Analysis
How is the GLPG UQS Score Calculated?
The UQS (Unified Quality Score) for Galapagos N.V. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Galapagos N.V.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Galapagos N.V. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.